EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PROTAC technology for prostate cancer treatment

Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei

Acta Materia Medica · 2025 · 4 (1)

DOI: 10.15212/amm-2024-0075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Materia Medica, 2025. Verfasst von Zhen Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 223 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites, such as bones, the pelvis, and various visceral organs. Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression, gene amplification, and the rise of androgen receptor splice variants. Although androgen deprivation therapy remains the mainstay for early-stage PrCa treatment, efficacy is temporary because many cases advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle. This review explores key biomarkers for PrCa and the latest therapeutic strategies for CRPC with a particular focus on the innovative proteolysis-targeting chimera (PROTAC) technology. This approach offers a novel means of degrading target proteins and we discuss how PROTAC holds potential as effective strategies to combat resistance mechanisms in CRPC.

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Wang, Z., Zhang, D., Inuzuka, H., & Wei, W. (2025). PROTAC technology for prostate cancer treatment. Acta Materia Medica, 4(1). https://doi.org/10.15212/amm-2024-0075

Vancouver

Wang Z, Zhang D, Inuzuka H, Wei W. PROTAC technology for prostate cancer treatment. Acta Materia Medica. 2025;4(1). doi:10.15212/amm-2024-0075

BibTeX
@article{Wang2025,
  author = {Wang, Zhen and Zhang, Dingpeng and Inuzuka, Hiroyuki and Wei, Wenyi},
  title = {PROTAC technology for prostate cancer treatment},
  journal = {Acta Materia Medica},
  year = {2025},
  volume = {4},
  number = {1},
  doi = {10.15212/amm-2024-0075}
}
Kostenlos starten →